|Articles|April 14, 2009

Coast Issued Warning Letter by FDA

To see FDA news on the warning letter the Agency has issued to coast, please click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

© photon_photo - © photon_photo - stock.adobe.com

What 2026 Will Demand From Clinical Operations: Rethinking Efficiency, Access, and AI

ByAndy Studna, Senior Editor

January 26th 2026

Where Real-World Evidence Fits Along the Clinical Research Spectrum

ByJen Lamppa,Andy Studna, Senior Editor

January 26th 2026

ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework

ByAndy Studna, Senior Editor

January 26th 2026

If You Build It ... Will They Come?

ByKen Getz, MBA

January 23rd 2026

Using De-Identified Data to Rethink Trial Design and Site Strategy

ByJen Lamppa,Andy Studna, Senior Editor

January 23rd 2026

Coast Issued Warning Letter by FDA

Newsletter

Related Content

What 2026 Will Demand From Clinical Operations: Rethinking Efficiency, Access, and AI

Where Real-World Evidence Fits Along the Clinical Research Spectrum

ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework

If You Build It ... Will They Come?

Using De-Identified Data to Rethink Trial Design and Site Strategy

Trending on Applied Clinical Trials Online

If You Build It ... Will They Come?

ACT Brief: De-Identified Data Expands Trial Design, Global Production Normalizes, and FDA Updates Quality Framework

Using De-Identified Data to Rethink Trial Design and Site Strategy

Congressional Funding Deal Boosts Research Space Ahead of Shutdown Deadline

Where Real-World Evidence Fits Along the Clinical Research Spectrum